{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:38:44Z","timestamp":1790167124044,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T00:00:00Z","timestamp":1513728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Stereotactic ablative radiotherapy (SABR) is an emerging therapy for primary renal cell carcinoma. The authors assessed safety, efficacy, and survival in a multi\u2010institutional setting. Outcomes between single\u2010fraction and multifraction SABR were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Individual patient data sets from 9 International Radiosurgery Oncology Consortium for Kidney institutions across Germany, Australia, the United States, Canada, and Japan were pooled. Toxicities were recorded using Common Terminology Criteria for Adverse Events, version 4.0. Patient, tumor, and treatment characteristics were stratified according to the number of radiotherapy fractions (single vs multiple). Survival outcomes were examined using Kaplan\u2010Meier estimates and Cox proportional\u2010hazards regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Of 223 patients, 118 received single\u2010fraction SABR, and 105 received multifraction SABR. The mean patient age was 72 years, and 69.5% of patients were men. There were 83 patients with grade 1 and 2 toxicity (35.6%) and 3 with grade 3 and 4 toxicities (1.3%). The rates of local control, cancer\u2010specific survival, and progression\u2010free survival were 97.8%, 95.7%, and 77.4%, respectively, at 2 years; and they were 97.8%, 91.9%, and 65.4%, respectively, at 4 years. On multivariable analysis, tumors with a larger maximum dimension and the receipt of multifraction SABR were associated with poorer progression\u2010free survival (hazard ratio, 1.16 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.01] and 1.13 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.02], respectively) and poorer cancer\u2010specific survival (hazard ratio, 1.28 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.01] and 1.33 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01], respectively). There were no differences in local failure between the single\u2010fraction cohort (n\u2009=\u20091) and the multifraction cohort (n\u2009=\u20092;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.60). The mean (\u2009\u00b1\u2009standard deviation) estimated glomerular filtration rate at baseline was 59.9\u2009\u00b1\u200921.9\u2009mL per minute, and it decreased by 5.5\u2009\u00b1\u200913.3\u2009mL per minute (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>\n                      SABR is well tolerated and locally effective for treating patients who have primary renal cell carcinoma and has an acceptable impact on renal function. An interesting observation is that patients who receive single\u2010fraction SABR appear to be less likely to progress distantly or to die of cancer.\n                      <jats:bold>\n                        <jats:italic>Cancer<\/jats:italic>\n                        2018;124:934\u201042.\n                      <\/jats:bold>\n                      \u00a9\n                      <jats:italic>2017 American Cancer Society<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncr.31156","type":"journal-article","created":{"date-parts":[[2017,12,20]],"date-time":"2017-12-20T23:23:45Z","timestamp":1513812225000},"page":"934-942","source":"Crossref","is-referenced-by-count":148,"title":["Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)"],"prefix":"10.1002","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-0658","authenticated-orcid":false,"given":"Shankar","family":"Siva","sequence":"first","affiliation":[{"name":"Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Center University of Melbourne Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology London Regional Cancer Program London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Warner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology London Regional Cancer Program London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muacevic","sequence":"additional","affiliation":[{"name":"Cyberknife Center University of Munich Hospitals Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilkumar","family":"Gandhidasan","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Center University of Melbourne Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ponsky","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Ellis","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irving","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Radiation Oncology Beth Israel Deaconess Medical Center Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Radiation Oncology Beth Israel Deaconess Medical Center Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Sunnybrook Health Sciences Centre and the University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Swaminath","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Juravinski Cancer Centre McMaster University Hamilton Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Radiology University of Yamanashi Yamanashi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Teh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Houston Methodist Hospital, Cancer Center and Research Institute Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohann J.","family":"Correa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology London Regional Cancer Program London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology University of Washington School of Medicine Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Staehler","sequence":"additional","affiliation":[{"name":"Cyberknife Center University of Munich Hospitals Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21262"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_8_4_1","volume-title":"SEER Cancer Statistics Review, 1975\u20102012","author":"Howlader N","year":"2015"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.03.006"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.04.016"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.08.088"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.01.005"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.183.1.1830201"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.87"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.16.2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-62-740-679"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11550.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.08.030"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.08.044"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13811"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23896"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.04.081"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.09.018"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0138"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.10.033"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.044"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11941116"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2016.01.027"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.14099"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.042"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70446-7"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70168-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:26:38Z","timestamp":1760279198000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,20]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/cncr.31156"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31156","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,20]]}}}